Biomarkers in head and neck cancer

Hyunseok Kang, Christine H. Chung, Arlene A. Forastiere

Research output: Chapter in Book/Report/Conference proceedingChapter


Biomarker research provides the opportunity to risk stratify patients based on identified prognostic and predictive markers. The need for such biomarkers is evident to improve response and survival outcomes in head and neck cancer through more rational patient selection for intensive curative regimens as well as palliative treatments. Advances in our understanding of genomics, epigenetics, and immunology of head and neck cancer are accelerating the discovery of new biomarkers. With the increasing availability of molecularly targeted therapeutics, it is very important to identify and validate biomarkers in the appropriate clinical setting to translate the advances into improved clinical outcome. This chapter focuses on human papillomavirus (HPV) status as a validated prognostic biomarker and discusses emerging prognostic and/or predictive biomarkers with potential for testing through prospective clinical trials. The availability of validated diagnostic assays and required multi-institutional trials for selected patients presents logistical challenges in biomarker research for head and neck cancer.

Original languageEnglish (US)
Title of host publicationHead and Neck Cancer: Multimodality Management, Second Edition
PublisherSpringer International Publishing
Number of pages14
ISBN (Electronic)9783319276014
ISBN (Print)9783319275994
StatePublished - Jan 1 2016


  • Head and neck cancer
  • Molecular biomarkers
  • Predictive and prognostic markers
  • Therapeutic targets

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Biomarkers in head and neck cancer'. Together they form a unique fingerprint.

Cite this